Seelos Therapeutics (NASDAQ:SEEL) shares are trading lower on Friday after the company announced an 8.865 million shares common stock offering at 79 cents per share.
Seelos Therapeutics is engaged in the pharmaceutical industry. The company's pipeline products include SLS-002 which is intranasal racemic ketamine for patients with suicidality in post-traumatic stress disorder and depressive disorder; SLS-006 which is a small molecule, partial dopamine agonist for Parkinson's Disease; and SLS-005 is Trehalose, a protein stabilizer.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Seelos Therapeutics shares were trading down 22.43% at 65 cents at the time of publication on Friday. The stock has a 52-week high of $1.70 and a 52-week low of 42 cents.
Related Link:
Seelos Therapeutics Shares Rally Following Deal For Gene Therapy Program
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.